Nanoparticle Trojan Horses Gallop From the Lab Into the Clinic

See allHide authors and affiliations

Science  15 Oct 2010:
Vol. 330, Issue 6002, pp. 314-315
DOI: 10.1126/science.330.6002.314

You are currently viewing the summary.

View Full Text

Log in to view the full text

Log in through your institution

Log in through your institution


Researchers have been engineering nanoparticles to ferry toxic medicines into tumor cells before they release their cargo. After many years of studies with cell cultures and animals, nearly a dozen nanoparticle-based drugs are in clinical trials, most of which aim at treating or diagnosing cancer. Many other compounds are progressing through preclinical studies and are nearing human trials. Although it will require several more years of testing to determine whether the compounds are safe and effective, researchers are optimistic that the results will be positive. That would be welcome news in the fight against cancer.